JPRN-UMIN000036809已完成未知
Study of the safety and efficacy of brachytherapy (HB-001) by alpha-particle sources for refractory head & neck and breast cancer - Clinical Study of HB-001 brachytherapy in Japan
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Hekabio K.K.
- 入组人数
- 14
研究概览
简要总结
Primary endpoint (efficacy) Efficacy was evaluated in 11 of 10 head and neck cancer patients with a modified FAS response rate of 81.8% (95% CI: 48.2-97.7), significantly higher than the threshold response rate of 30%. The response rate for three lesions was 66.7% (95% CI: 9.4-99.2), although the number of breast cancer patients could not be evaluated for efficacy because the target number of patients was not reached.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •>The size of the tumor more than 5 cm in the maximum diameter. >ECOG performance status is 3 or higher 3: Capable of only limited selfcare. Confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair >Continuously receiving medication that may have a significant impact on the evaluation of safety or efficacy, such as immunosuppressants and/or corticosteroids. >History of serious allergy to the medicine for the treatments like anesthesia. >There are tumors to be preferentially treated such as metastatic lesion other than the target tumor >Having received chemotherapeutic drugs (except hormonal agents), immunotherapeutic agents, and molecular targeting agents in the past 30 days, which may affect the assessment of the safety or efficacy of the HB-001 brachytherapy. >Having received immune checkpoint inhibitor in the past 2 months, which may affect the assessment of the safety or efficacy of the HB-001 brachytherapy. >Having participated in different clinical studies in the past 30 days, which may affect the assessment of the safety or efficacy of HB-001 brachytherapy >Pregnant women or breast-feeding mothers >Those who do not wish to sign the informed consent form
研究者
相似试验
终止
2 期
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate CancerProstate CancerNCT01374087Ipsen32
终止
2 期
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisIBDNCT03616821AstraZeneca242
已完成
不适用
Intraluminal brachytherapy treatment results analysis of unresectable recurrent cholangiocarcinomaNeoplasmsKCT0000738Chonbuk National University Hospital30
Unknown
2 期
Safety of 32P BioSilicon in Patients With Hepatocellular CarcinomaLiver CancerNCT00247260pSiVida Limited50
已完成
不适用
High-Dose Brachytherapy in Treating Patients With Prostate CancerProstate AdenocarcinomaStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerNCT02346253Stanford University146